56
Participants
Start Date
August 4, 2014
Primary Completion Date
February 6, 2016
Study Completion Date
April 23, 2018
SGI-110 administration
"SGI-110 will be administered SC at 60 mg/m²/day x5 consecutive days for each cycle. Cycle duration is 28 days. Patients with Complete Remission (CR), Partial Remission (PR), marrow CR or Hematological Improvement (HI) after 6 Cycles of therapy (IWG 2006 criteria) may continue treatment until progression.~A dose reduction to 45 and even 30 mg/m²/day will be made in case of haematological toxicity. Patients with no response (NR) to treatment will be withdrawn from the protocol after the last treatment Cycle."
Hôpital Paoli Calmettes, Marseille
CHU Clémenceau, Caen
Chu Purpan, Toulouse
CHU de Haut-Lévèque, Pessac
Clinique Beausoleil (Montpellier), Montpellier
CHU Bretonneau, Tours
CHU de Grenoble, Grenoble
CHU de nantes, Nantes
Centre Catherine de Sienne (Nantes), Nantes
CHR Orléans, Orléans
CHU Brabois, Vandœuvre-lès-Nancy
Centre Hospitalier de La Cote Basque, Bayonne
Centre Hospitalier Joffre, Perpignan
CH Lyon Sud, Lyon
Centre Hospitalier du Mans, Le Mans
Centre Hospitalier de la région d'Annecy, Pringy
Hopital St Louis T4, Paris
Centre Henri Becquerel, Rouen
Centre Hospitalier de Meaux, Meaux
CH Avignon, Avignon
CHU de Poitiers, Poitiers
CHRU Limoges, Limoges
CHU Henri Mondor, Créteil
CH Angers, Angers
Hôpital Avicenne, Bobigny
CHU de Nice - Hopital de l'Archet 1, Nice
Hopital Purpan Service d'Hématologie Clinique, Toulouse
Collaborators (1)
Astex Pharmaceuticals, Inc.
INDUSTRY
Groupe Francophone des Myelodysplasies
OTHER